Author

Alica K. Michels

University of California, IrvineORCID 0009-0005-9573-0333Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Christopher J. HalbrookiD· 2 shared Alexander MuiriD· 1 shared Anika T. Thomas-TothiD· 1 shared Ashley GeorgeiD· 1 shared Austin D. SilvaiD· 1 shared Cecily AnarakiiD· 1 shared Christopher R. WeberiD· 1 shared Colin S. SheehaniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christopher J. HalbrookORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCellular and Molecular Gastroenterology and HepatologyPeer-reviewedSep 5, 2026

Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis

Rima Singh, Natalie Yousefian, Walker M. Allen…·Christopher J. Halbrook

The paper compares primary and liver PDAC lesions using single-cell transcriptomics to identify MET as a target in pancreatic cancer metastasis.

1 citation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 4, 2025

Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer

Colin S. Sheehan, Lyndon Hu, Guillaume Cognet…·Alexander Muir

This study shows that pancreatic cancer cells in a nutrient-stressed tumor microenvironment develop drug tolerance, and identifies BCL-XL inhibition as a potential therapeutic strategy.

DOI 10.1101/2025.09.04.673818

mousebulk RNA-seq

𝕏 PostBluesky